# NCT03530683 (NCT03530683)

> A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: maplirpacept; maplirpacept plus azacitidine; maplirpacept plus azacitidine plus venetoclax
- Indication: advanced hematologic malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03530683
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Pfizer
- Conditions: Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma
- Interventions: Maplirpacept (PF-07901801); Azacitidine; Venetoclax; Carfilzomib; Dexamethasone; Anti-CD20 Targeting agent; Isatuximab
- Enrollment: 189
- Primary outcome: Phase 1a: Number of adverse events (AE) by severity
- Primary outcome: Phase 1a: Number of AEs by Frequency
- Primary outcome: Phase 1a: Number of participants with Dose-Limiting Toxicities (DLT)
- Primary outcome: Phase 1b: Number of adverse events (AE) by severity
- Primary outcome: Phase 1b: Number of adverse events (AE) by frequency
- Primary outcome: Phase 1b: Number of participants with disease response
- Primary outcome: Phase 1a: Maximum Tolerated Dose (MTD)
- Primary outcome: Phase 1b: Recommended dose of TTI-622 in combination with selected anticancer treatments
- Primary outcome: Phase 1b: Recommended dose of TTI-622 as a single agent
- Primary outcome: Number of participants with response assessments that show preliminary efficacy

## Indexed commentary on NCT03530683 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03530683